Weigang Wang1, Xiaoqin Xu1, Baoguo Tian1, Yan Wang1, Lili Du1, Ting Sun1, Yanchun Shi1, Xianwen Zhao1, Yali Jia2, Yanfeng Xi3, Jiexian Jing1
1.Department of Etiology and tumor marker laboratory, Shanxi Cancer Hospital,Shanxi province, China.
2. Department of preventive health care, Shanxi Cancer Hospital, Shanxi province, China.
3. Department of Pathology, Shanxi Cancer Hospital, Shanxi province, China.
Jiexian Jing for correspondence:email@example.com
Aim This study aims to understand the clinical features, treatment, and prognosis of male breast cancer (MBC) patients in Shanxi province of China from 2007 to 2016.
Data for 77 MBC patients were collected for analysis. Immunohistochemistry, pathological results, and other data such as demographic characteristics (age, marital status, smoking history, drinking history, and family history of cancer) as well as clinical data were investigated by retrieving information from the patient's medical records.
A total of 12404 patients were diagnosis with breast cancer between 2007 and 2016, and among them, 77 were MBC patients. The median diagnosis age of MBC patients was 62 years (range, 24 to 84 years). The most common complaint was a painless lump in the breast, accounting for 68.8% of the patients, and the main pathological type in MBC was infiltrating ductal carcinoma (66.2%). In terms of hormone receptors, 80.5% (62/77) of MBC patients were estrogen receptor (ER) positive, 75.3% (58/77) of patients were progesterone receptor (PR) positive, and only
6.5% (5/77) of patients were HER2 over expressing. 88.3% (68/77) of MBC patients underwent surgery, 66.2% (51/77) of the patients received adjuvant chemotherapy, and 16.2% (16/77) of the patients accepted radiation therapy. By the end of the follow-up date, a total of 47 patients had survived, 15 patients died due to breast cancer, two patients died of other diseases, and 13 patients were lost with information about them. The Cox regression analysis showed that M stage is the only factor significantly associated with overall survival (P=0.018, HR=18.791, 95%CI, 1.663 to 212.6).
The epidemiological and clinical features of Chinese MBC are similar to that of other countries. As the Chinese public has limited knowledge of MBC, it is necessary to increase awareness among them about it. Further research with a large sample size is required for better understanding of the risks associated with MBC.